Shigella genus of bacteria is composed of four different species -S.sonnei, S.flexneri, S.boydii and S.dysenteriae -based on the O antigens from their lipopolysaccharide walls. 3 A global study estimated that S.flexneri (65.9%) followed by S.sonnei (23.7%) are the most common serotypes identified in lowand middle-income countries as the cause of shigellosis in children younger than five years of age, 4 in contrast to Australian national data that show that S.sonnei (71%) and S.flexineri (27%) are the most common serotypes found across all age groups. 5 Infection with Shigella bacteria causes shigellosis, with clinical manifestations ranging from mild diarrhoea to severe dysentery, fevers, stomach cramps and dehydration. 6 Shigella has a low infectious dose 7 and is transmitted via the faecal-oral route as a result of inadequate hygiene practices related to hand washing, food handling or sexual activity. [8] [9] [10] Between 2009 and 2014, shigellosis rates in Australia doubled. 11 Laboratory testing data from Queensland during this period suggests that this increase was due largely to an increase in culture independent testing, 12 although there is no publicly available data to confirm this is the case in other jurisdictions.
In NSW, shigellosis is a notifiable disease under the Public Health Act 2010, 13 Consideration should therefore be given to whether PCR could be considered definitively diagnostic for some diseases, such as shigellosis, in addition to culture testing. In recent years a new PCR target, the ipaH gene, has been increasingly used to detect Shigella in stool samples. 17, 18 However, as this gene is present in both EIEC and Shigella 20 and, as EIEC is not a notifiable disease in Australia, the use of this gene for the diagnosis of shigellosis must factor in a possible alternative diagnosis of EIEC when setting case definitions. A previous Victorian study 21 examined the epidemiological differences between culture-positive and culture-negative (but ipaH PCR-positive) cases of shigellosis to help inform discussions about a change in national case definitions; however, this has not been repeated in other jurisdictions. We therefore audited a series of culture-positive and culture-negative (but ipaH PCR-positive) cases of shigellosis in the high-prevalence area of Sydney LHD (SLHD), NSW, to determine whether there are any significant differences between these groups to provide further evidence for determining whether a change to the national case definition for shigellosis should be recommended.
Methods
In accordance with NSW public health guidelines, 22 
Results
Of the 148 shigellosis cases notified during the study period, 26 (18%) were excluded as LTFU, resulting in 122 cases (85 culture positive and 37 culture negative) included for analysis ( Figure 1 ). There were no significant differences in gender (χ 2 = 3.03, p=0.069) or classification (i.e. culture positive versus negative, χ 2 = 2.42, p=0.119) between included and excluded cases. Table 1 shows the demographic characteristics, clinical details, and risk factors of the included cases, and the breakdown of these by culture result status. There was no statistically significant difference in the median age of cases between groups ( Table  1 ). The most frequent symptoms reported by all cases were diarrhoea (n=118, 97%), abdominal pain (n=98, 80%) and fever (n=79, 65%). Cases with a culture-positive result were significantly more likely to have experienced three or more symptoms than those with a culture-negative result (OR 3.18, 95%CI 1.3-7.5), and significantly more likely to have been hospitalised (OR 4.2, 95%CI 1.4-13.2), see Table 1 . Culture-negative cases had a significantly longer duration of symptoms compared to culture-positive cases (9.5 days versus 7 days, p<0.05); Table 1 . Culturepositive cases had a significantly shorter duration between symptom onset date and specimen collection date than culturenegative cases (median difference = 4 days, p<0.05), and were also significantly more * LTFU = lost-to-follow-up. # N/A -result not available, both cases were unable to be cultured and therefore presumed to be negative. 
Notes

Discussion
This study confirmed some previously identified epidemiological differences between Shigella culture-positive and Shigella culture-negative/PCR-positive cases in Victoria, 21 including the difference in time between symptom onset and specimen collection, and risk factors for disease. However, this review also uniquely identified differences in clinical severity between culture-positive and culturenegative/PCR-positive cases by number of symptoms reported and hospitalisation rates. Identifying these additional epidemiological differences in NSW adds to the evidence base for informing potential recommendations for changes to the national shigellosis case definition. 12, 21 However, before changes can be recommended, further studies on the laboratory differentiation of culture-negative/ PCR-positive cases are required to determine the true prevalence of Shigella versus EIEC in this group of cases that are currently excluded from public health follow-up in NSW and some other jurisdictions. Determining the true burden of shigellosis throughout Australia is important for public health control.
Our study suggests that culture-positive cases may experience a more clinically severe illness, with a greater number of symptoms and increased chance of hospitalisation than culture-negative/PCR-positive cases. Our finding of differences in clinical severity may be partially explained by evidence that indicates that EIEC expresses less virulence genes than Shigella 24, 25 and therefore can present as a less severe clinical illness. 26 However, without further laboratory testing data on the differentiation between EIEC and Shigella for culture-negative/ipaH PCR-positive cases in our study, we cannot determine whether a subset of cases in the culture-negative group were in fact EIEC, or whether the differences in clinical severity between groups can be explained by inherent differences in the clinical presentation of shigellosis.
In support of the finding that culture-positive cases may present with a more severe illness (or indeed vice versa), we found that culturepositive cases had a significantly shorter time to stool collection and duration of illness compared to culture-negative cases. Cases of shigellosis experiencing a more severe illness (e.g. with multiple symptoms or persistent or bloody diarrhoea) may be more likely to present earlier to a medical practitioner for assessment, diagnosis and treatment, than for other infectious diseases. 27 An earlier collection of stool for diagnostic testing may also lead to a higher bacterial load and viability for culture and/or PCR testing. 28 Studies show that those who present earlier are more likely to be given treatment earlier, accounting for a shorter overall duration of symptoms. 29 In contrast to the above findings, we found that culture-negative cases have a significantly longer time to stool collection and duration of symptoms compared to culture-positive cases. This finding is consistent with evidence that suggests that most cases of acute infectious diarrhoea are self-limiting, 30, 31 and general practitioners are recommended to take stool specimens from patients with acute infectious diarrhoea only when symptoms are severe and/or persistent. 32 This means that cases with mild illness may not present to medical care or, if they do, are likely to present later in their illness (when symptoms persist) and their type and level of symptoms at the point of care determine whether a stool sample is collected.
In line with previously described results in Victoria, 21 we found that culture-positive cases were more likely to have MSM contact identified as their most likely source of infection, compared to culture-negative cases, who were more likely to have acquired their infection overseas. This finding may be partially related to health seeking behaviour of gay men and increased awareness of sexual transmission of shigellosis in Australia. 33 In the past decade, there have been several outbreaks of shigellosis among the gay community in Australia, 34, 35 prompting © 2018 Sydney Local Health District media campaigns in NSW encouraging symptomatic people to present to health services for testing, 36 and therefore this may lead to higher shigellosis detection rates in this risk group. In addition, the finding that culture-negative cases were more likely to be acquired overseas and were clinically less severe may relate to detection of EIEC in the culture-negative/PCR-positive group, in line with published evidence suggesting that E.coli versus Shigella was the cause of travellers' diarrhoea for residents of southern hemisphere countries for 35% vs. 5% of specimens tested globally. 37, 38 There is growing evidence for the need to consider whether Shigella culture-negative/ PCR-positive cases should be included in the national surveillance case definition for shigellosis. 21 Three jurisdictions in Australia do not automatically exclude culture-negative/ ipaH PCR-positive cases and classify them as "Shigella species not typed", "Shigella not specified" or "probable Shigella/EIEC". 21 Recently, the US 39 and the UK 40 have updated their national public health guidelines to include the use of clinical, epidemiological and laboratory criteria (including the use of ipaH PCR), to help differentiate possible, probable and confirmed cases of shigellosis. If a 'probable' case definition for culture-negative/ PCR-positive cases were to be included in the national shigellosis public health case definition, cases with milder illness could be detected, providing surveillance data that would enable a better estimate of the burden of shigellosis in the community. In addition, if the public health risk of transmission was assessed to be high from these mild cases (e.g. cases with persistent diarrhoea), particularly to at-risk groups 41 (including young children, food handlers and elderly people), 22 then followup and contact tracing might also assist in disease control activity in the Australian setting. For example, the UK public health guidelines recommend public health action (i.e. education, hygiene advice and exclusion) only for probable and confirmed cases where a risk assessment has determined that either the case or their contacts are in a high-risk group (such as those listed above). 40 However, as the current PCR target cannot differentiate between Shigella and EIEC, the true burden of shigellosis is unlikely to be known until a more specific test is developed. Multiplex PCR assays are being developed to help differentiate ipaH PCR-positive stool samples, 24, 42 based on the differential expression of genes between E.coli and Shigella, e.g. lacY (a lactose permease gene). Two previous studies 43, 44 found that 100% of their Shigella stool sample isolates were ipaH positive/lacY negative, whereas their EIEC isolates were more likely to be ipaH positive/ lacY positive.
Until such a multiplex PCR test is available routinely in Australia, the inclusion of a "probable Shigella/EIEC" case definition for culture-negative/ipaH PCR-positive cases in the national case definition should be considered, with further laboratory differentiation to identify true Shigella versus EIEC cases among ipaH PCR-positive cases as needed. The additional public health follow-up of these cases could assist in the control of both Shigella and EIEC, which are clinically managed in the same way, 45 and thus provide a greater public health benefit for the population. In the future, even if a cost-effective and highly specific PCR assay for Shigella is developed, there will continue to be a need for some culture testing on PCRpositive samples in order to monitor serotype changes and antibiotic resistance to help guide treatment options.
There are several limitations to the collection and analysis of these data. Firstly, as the study was retrospective, there may have been incomplete case ascertainment and there were missing data for a number of cases; however, we found no significant differences by sex or classification between the cases included in the analysis and those excluded from our study, i.e. those LTFU. Secondly, this audit reviewed data only within one LHD in NSW and the results may not be able to be generalised across the rest of NSW. SLHD receives 24% of all notifications in NSW 14 and shigellosis cases occur predominantly in those identifying as MSM, which is not representative of other regions in NSW.
Thirdly, we were unable to account for some factors that could influence PCR and/or culture positivity rates in our study population. These include differences in referral for testing from general practice or hospitals (particularly for cases with mild versus severe disease) and the differences in diagnostic pathways (i.e. specimen preparation and the timing and use of PCR) in laboratories across NSW during the study period. Several laboratories provided diagnostic services for enteric investigation during the study period (n=9). Laboratories across NSW have historically used microscopy, culture and sensitivity testing on all stool samples for enteric bacterial investigation. PCR for diagnosis of shigellosis was introduced at different times across laboratories in NSW and was not used routinely in most public and private laboratories until about 2013 onwards.
Finally, we were unable to report on some factors that might influence the epidemiological differences found in our study. For example, the data on time to initiation of antibiotic therapy were relatively incomplete and unable to be reported; however, it is well established that antibiotics reduce symptom duration. 29 In addition, we did not use the case's actual reported symptom onset date due to missing data, and instead used the more complete 'calculated onset date' in the calculation of some variables to ensure consistency among cases. This may have had some impact on calculated symptom duration. We also do not routinely collect any laboratory data on infectivity or pathogen shedding at diagnosis (or indeed after treatment) and therefore could not account for any differences in the infectivity of culture-positive versus negative cases, which may have helped with the recommendation on prioritisation of public health action for culture-positive versus negative (but ipaH positive) cases of shigellosis.
Conclusions
This study confirmed some epidemiological differences previously identified in Victoria between Shigella culture-positive and Shigella culture-negative/ipaH PCR-positive cases, including time between symptom onset and specimen collection and risk factors for disease, in NSW. The finding that culturepositive cases may experience a more severe clinical illness than culture-negative/ipaH PCR-positive cases is a new finding and requires further investigation. As the currently used ipaH PCR test does not differentiate between Shigella and EIEC, it is not possible to determine if the differences in clinical severity in this study were due to the detection of EIEC in the culture-negative group, or an inherent difference in the presentation of shigellosis. Further studies on the laboratory differentiation of culture-negative/ipaH PCRpositive cases are needed in the Australian context to determine the true prevalence of Shigella versus EIEC among this group. Until a more specific PCR assay is available for the diagnosis of shigellosis, consideration should be given to the use of a "probable Shigella/ EIEC" case definition for culture-negative/ ipaH PCR-positive cases in Australia, with follow-up likely to reduce the public health burden of these two diseases.
